IL244742A0 - A selective phosphatidylinositol-3-kinase-gamma inhibitor, preparations containing it and its uses - Google Patents

A selective phosphatidylinositol-3-kinase-gamma inhibitor, preparations containing it and its uses

Info

Publication number
IL244742A0
IL244742A0 IL244742A IL24474216A IL244742A0 IL 244742 A0 IL244742 A0 IL 244742A0 IL 244742 A IL244742 A IL 244742A IL 24474216 A IL24474216 A IL 24474216A IL 244742 A0 IL244742 A0 IL 244742A0
Authority
IL
Israel
Prior art keywords
phosphatidylinositol
kinase
gamma
compositions
same
Prior art date
Application number
IL244742A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IL244742A0 publication Critical patent/IL244742A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL244742A 2013-09-25 2016-03-23 A selective phosphatidylinositol-3-kinase-gamma inhibitor, preparations containing it and its uses IL244742A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882473P 2013-09-25 2013-09-25
PCT/US2014/057499 WO2015048318A1 (en) 2013-09-25 2014-09-25 A selective inhibitor of phosphatidylinositol 3-kinase-gamma

Publications (1)

Publication Number Publication Date
IL244742A0 true IL244742A0 (en) 2016-04-21

Family

ID=51795739

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244742A IL244742A0 (en) 2013-09-25 2016-03-23 A selective phosphatidylinositol-3-kinase-gamma inhibitor, preparations containing it and its uses

Country Status (17)

Country Link
US (1) US10301304B2 (enExample)
EP (2) EP3412668B1 (enExample)
JP (1) JP6340416B2 (enExample)
KR (1) KR20160058950A (enExample)
CN (1) CN105722838B (enExample)
AU (1) AU2014324873B2 (enExample)
BR (1) BR112016006388A2 (enExample)
CA (1) CA2925601C (enExample)
CL (1) CL2016000695A1 (enExample)
ES (2) ES2785053T3 (enExample)
IL (1) IL244742A0 (enExample)
MX (1) MX2016003823A (enExample)
RU (2) RU2018142605A (enExample)
SG (2) SG10201802061TA (enExample)
UA (1) UA117032C2 (enExample)
WO (1) WO2015048318A1 (enExample)
ZA (1) ZA201702252B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051244A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3119397B1 (en) 2014-03-19 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017004079A1 (en) 2015-06-29 2017-01-05 Biomed Valley Discoveries, Inc. Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
KR20180117693A (ko) * 2016-03-10 2018-10-29 아스트라제네카 아베 포스파티딜이노시톨 3-키나제 감마의 신규 억제제
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114025756B (zh) * 2019-04-10 2022-09-27 南京征祥医药有限公司 磷脂酰肌醇3-激酶抑制剂
CN114206332B (zh) 2019-06-04 2024-08-23 艾库斯生物科学有限公司 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228892A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071717A1 (es) * 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2842399T3 (es) * 2009-12-22 2021-07-14 Vertex Pharma Inhibidores isoindolinona de fosfatidilinositol 3-quinasa

Also Published As

Publication number Publication date
ES2785053T3 (es) 2020-10-05
EP3049415A1 (en) 2016-08-03
ES2687593T3 (es) 2018-10-26
AU2014324873B2 (en) 2018-11-08
CA2925601C (en) 2022-11-01
CN105722838B (zh) 2017-10-24
WO2015048318A1 (en) 2015-04-02
CN105722838A (zh) 2016-06-29
SG10201802061TA (en) 2018-05-30
EP3412668A3 (en) 2018-12-19
CL2016000695A1 (es) 2017-06-09
MX2016003823A (es) 2016-08-01
RU2018142605A (ru) 2019-02-04
US10301304B2 (en) 2019-05-28
BR112016006388A2 (pt) 2017-08-01
EP3049415B1 (en) 2018-07-04
ZA201702252B (en) 2019-06-26
EP3412668B1 (en) 2020-02-05
RU2016115726A (ru) 2017-10-30
AU2014324873A1 (en) 2016-04-21
HK1223620A1 (zh) 2017-08-04
SG11201602265PA (en) 2016-04-28
JP2016531861A (ja) 2016-10-13
EP3412668A2 (en) 2018-12-12
CA2925601A1 (en) 2015-04-02
RU2016115726A3 (enExample) 2018-06-20
US20160214980A1 (en) 2016-07-28
UA117032C2 (uk) 2018-06-11
KR20160058950A (ko) 2016-05-25
RU2675814C2 (ru) 2018-12-25
JP6340416B2 (ja) 2018-06-06

Similar Documents

Publication Publication Date Title
IL244742A0 (en) A selective phosphatidylinositol-3-kinase-gamma inhibitor, preparations containing it and its uses
IL267681A (en) Selective grp94 inhibitors and their uses
IL241330B (en) pk - dna suppressor compounds, preparations containing them and their uses
IL240196B (en) Amide compounds, preparations containing them and their uses
IL238958A0 (en) Glutamase inhibitors, preparations containing them and their uses
IL240239A0 (en) erk inhibitors and their uses
IL241225A0 (en) Plant-based compositions and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
EP2943202A4 (en) IRAQ INHIBITORS AND USES THEREOF
EP3049086A4 (en) Irak inhibitors and uses thereof
IL244432B (en) Aza-pyridone compounds and their uses
IL269964A (en) Pyridone amide compounds, compositions containing them and uses thereof
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
GB201323008D0 (en) Compounds and uses thereof
IL240553A0 (en) il-1ß inhibitory compounds and use thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
IL239762A0 (en) Selective nox-1 blocking peptides and their use
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201307233D0 (en) Compounds and uses thereof
EP3039009A4 (en) Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof
EP2967055A4 (en) BIOCIDAL COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE
HK1227408A1 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
HK1228284A1 (en) Jak1 selective inhibitor and uses thereof
GB201308242D0 (en) Compositions and uses thereof
SG11201507720PA (en) Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor